The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
 
Nizar M. Tannir
Honoraria - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Ipsen; Lilly; Nektar; Novartis; Oncorena; Ono Pharmaceutical; Pfizer; Surface Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Nektar; Novartis; Oncorena; Ono Pharmaceutical; Pfizer; Surface Oncology
Research Funding - Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Mirati Therapeutics; Nektar; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Ipsen; Lilly; Nektar; Novartis; Onco Pharmaceuticals; Oncorena; Pfizer; Surface Oncology
 
David F. McDermott
Consulting or Advisory Role - alkermes; Array BioPharma; Bristol-Myers Squibb; EMD Serono; exelixis; Genentech/Roche; Jounce Therapeutics; Lilly; Merck; Novartis; Peloton Therapeutics; Pfizer
Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Prometheus (Inst)
Other Relationship - Beth Israel Deaconess Medical Center
(OPTIONAL) Uncompensated Relationships - AVEO; X4 Pharma
 
Bernard Escudier
Honoraria - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Oncorena; Pfizer; Roche/Genentech
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Pfizer; Roche/Genentech
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; MSD; Pfizer; Roche/Genentech
 
Hans J. Hammers
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - ARMO BioSciences; Bayer; Bristol-Myers Squibb; exelixis; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck
 
Osvaldo Rudy Aren
Employment - Pfizer (I)
Stock and Other Ownership Interests - Pfizer (I)
Honoraria - Pfizer (I)
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb
Travel, Accommodations, Expenses - Roche; Tecnofarma
 
Elizabeth R. Plimack
Consulting or Advisory Role - Bristol-Myers Squibb; Clovis Oncology; Exelixis; Flatiron Health; Genentech/Roche; Incyte; Janssen; Merck; Seagen
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Peloton Therapeutics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst)
 
Philippe Barthelemy
Honoraria - Astellas Pharma; EUSA Pharma
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Amgen
 
Victoria Neiman
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Teva
Consulting or Advisory Role - Merck Sharp & Dohme
 
Saby George
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; EMD Serono; Exelixis; Genentech/Roche; Janssen Oncology; Pfizer; Sanofi
Research Funding - Agensys (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst)
 
Camillo Porta
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EUSA Pharma; GE Healthcare; Ipsen; Merck Sharp & Dohme; Pfizer
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Eisai; EUSA Pharma; GE Healthcare; Ipsen; Janssen; Merck Sharp & Dohme; Pfizer
Research Funding - Pfizer (Inst)
Expert Testimony - EUSA Pharma; Pfizer
Travel, Accommodations, Expenses - Roche
 
Thomas Powles
Honoraria - AstraZeneca; Bristol-Myers Squibb; Ferring; Gerson Lehrman Group; Janssen Research & Development; MERCK; Novartis; Pfizer; Roche/Genentech; Seattle Genetics/Astellas
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Incyte; Ipsen; Merck; Novartis; Novartis; Pfizer; Seagen
Research Funding - AstraZeneca/MedImmune; Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Ferring; MSD; Novartis/Ipsen; Pfizer; Research to Practice; Roche/Genentech
 
Frede Donskov
Research Funding - Ipsen (Inst); Pfizer (Inst)
 
Marc-Oliver Grimm
Honoraria - Apogepha; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Medac; MSD; Novartis; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Health; Bristol-Myers Squibb; Hexal; Intuitive Surgical; Ipsen; Janssen-Cilag; Merck; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche
Research Funding - Bristol-Myers Squibb (Inst); Intuitive Surgical (Inst)
Travel, Accommodations, Expenses - Bayer Health; Bristol-Myers Squibb; Merck Serono
 
Asim Amin
Consulting or Advisory Role - Merck; Novartis
Speakers' Bureau - Bioarray Therapeutics; Bristol-Myers Squibb; Exelixis; Merck; Novartis; Sanofi/Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); Merck (Inst)
 
Scott S. Tykodi
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Jounce Therapeutics (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending (Inst)
 
Yoshihiko Tomita
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Novartis; Ono Pharmaceutical
Consulting or Advisory Role - Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma; AstraZeneca; Chugai Pharma; Ono Pharmaceutical; Pfizer
 
Brian I. Rini
Leadership - MJH Life Sciences
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Merck; Peloton Therapeutics; Pfizer; Roche/Genentech; Surface Oncology; synthorx
Research Funding - AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Pfizer
 
M. Brent McHenry
Employment - Bristol-Myers Squibb
Leadership - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
 
Shruti Shally Saggi
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Incyte; Lilly; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); Novartis (Inst); Pfizer (Inst)